Toxicity and neuropharmacology of cyclopiazonic acid.
Cyclopiazonic acid (CPA) was found to have many pharmacological properties in common with the antipsychotic drugs chlorpromazine and reserpine. Thus, in mice CPA at ip doses of 5-14 mg/kg body weight produced hypokinesia, hypothermia, catalepsy, ptosis, sedation without loss of righting reflex, tremor, gait disturbance, dyspnoea, opisthotonus, atypical convulsion and prolonged barbiturate-induced sleep. The ip LD50 of CPA was found to be 13 +/- 0.05 mg/kg. The tremors induced by near-lethal doses of CPA were associated with voluntary or forced movements (action tremors); they worsened during the days following treatment, but they were weak compared with the exhausting and continuous tremors of the whole body caused by 20 mg tremorine/kg (used for comparison). When death occurred only 24-259 min after administration of CPA (11-14 mg/kg), it was preceded by dypsnoea, cyanosis, opisthotonus and clonic leg movements and tonic extension of hind legs (convulsions). When death was delayed (2-6 days after CPA administration), it was preceded by prostration, ptosis, hypothermia, tremor and cessation of food and water intake resulting in cachexia; convulsions were not seen in this group of mice. CPA did not affect the rate of convulsion or death caused by either maximal electroshock or metrazol administration but it did delay the onset of metrazol-induced seizures. In rabbits, 10 mg CPA/kg body weight initially produced tachycardia, tachypnoea and sedation with an activated electroencephalogram. Of three rabbits given 10 mg CPA/kg one died, and in this rabbit slow delta waves were seen just before and during a brief period with clonic leg movements. In this animal death was accompanied by tonic extension of the hind legs, respiratory arrest and cardiac fibrillation; and epileptiform EEG was not seen at any time. The unexpected EEG activation with sedation in rabbits treated with CPA was similar to the effect of reserpine on EEG.
D000818:Animals; D001835:Body Weight / Q000187:drug effects; D002746:Chlorpromazine / Q000494:pharmacology; D004562:Electrocardiography; D004569:Electroencephalography; D006339:Heart Rate / Q000187:drug effects; D006591:Hexobarbital / Q000494:pharmacology; D007035:Hypothermia / Q000139:chemically induced; D007211:Indoles / Q000633:toxicity*; D007274:Injections, Intraperitoneal; D007928:Lethal Dose 50; D008297:Male; D051379:Mice; D009069:Movement Disorders / Q000139:chemically induced*; D011817:Rabbits; D012110:Reserpine / Q000494:pharmacology; D012119:Respiration / Q000187:drug effects; D012890:Sleep / Q000187:drug effects; D013045:Species Specificity
D007211:Indoles; D012110:Reserpine; D006591:Hexobarbital; D002746:Chlorpromazine; C000543:cyclopiazonic acid